ClinicalTrials.gg
Active, not recruitingNCT06065657KAMUpdated Apr 7, 2026

Effect of Nutritional Ketosis on Alcohol Metabolism

A Phase 2/3 interventional study of Ketone Supplement and Control Diet in Ketoses, Metabolic, Ketogenic Dieting and Alcohol Intoxication, sponsored by University of Pennsylvania. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by University of Pennsylvania · Phase 2/3, Interventional, and Basic science

Phase
Phase 2/3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

The research study is being conducted in health controls to better understand the effects of ketosis on brain functioning after 3 different, randomly assigned, 3-day dietary interventions and the acute effects of alcohol after consuming about 4-5 alcohol beverages. The labs visits will use magnetic resonance imaging (MRI) scans to study the brain, measuring levels of nicotinamide adenine dinucleotide (NAD), lactate, neurotransmitters glutamate, and Gamma-aminobutyric acid (GABA).

Read the detailed description

The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Healthy participants will undergo three randomly assigned dietary interventions, each lasting three days, followed by a study lab visit day on day 4. The three interventions are: (1) Eat a ketogenic diet for 3 days, (2) eat a control diet for 3 days with a ketone supplement drink, and (3) eat a control diet for 3 days. The dietary interventions will be spaced 1 week apart. The ketone supplement drink "bis-octanoyl (R)-1,3-butanediol" (Kenetik: Ketone Drink, VitaNav Inc., Washington D.C.) 12.5g of ketones, TID PO (by mouth).) is a dietary supplement that has been extensively studied in humans and is designated by the FDA as Generally Recognized as Safe (GRAS). Its use in this study is experimental. On the day of the 3 labs visits days, magnetic resonance imaging (MRI) will be used to study the brain. Specifically, levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Following the scans, participants will be provided a dose of alcohol that will elevate participants breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol.

02

Conditions studied

  • Ketoses, Metabolic
  • Ketogenic Dieting
  • Alcohol Intoxication
  • Magnetic Resonance Imaging
  • Alcohol Drinking

Keywords

  • Ketone supplement
03

In context

Ketosis

218 studies on the registry are indexed under Ketosis; 50 are open to participants now.

This study's enrollment of 23 is above the median of 20 across 190 interventional studies indexed under Ketosis.

Browse Ketosis studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness to provide signed, and commit to completing study procedures.
  2. Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.
  2. Current , Fifth Edition (DSM-5) diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.
  3. Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)
  4. Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).
  5. A current, physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).
  6. Currently suffering from or has a history of stroke and/or stroke related spasticity.
  7. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).
  8. Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).
  9. Females who are pregnant or breast-feeding
  10. to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his/ her back for up to 2 hrs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Ketogenic diet

    Eat a ketogenic diet for 3 days

    Drug: Ethanol

  • Placebo comparator
    Control Diet

    Eat a control diet for 3 days

    Drug: Ethanol

  • Experimental
    Ketone supplement

    Eat a control diet for 3 days with a ketone supplement drink

    Other: Control Diet · Drug: Ethanol

  • Experimental
    Alcohol Intervention

    Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%

    Dietary Supplement: Ketone Supplement · Other: Control Diet · Other: Ketogenic diet

Interventions

  • Dietary supplementKetone Supplement

    Drug pages: 3-Hydroxybutyric Acid · Butylene glycol · Butylene Glycols

    Ketone supplement 3x day with control diet for 3 days.

    Also known as: D-Beta-hydroxybutyric acid and R-1,3 butanediol

  • OtherControl Diet

    Control Diet breakfast, lunch, and dinner for 3 days.

    Also known as: ~ 50% kcal carbohydrates diet

  • OtherKetogenic diet

    Ketogenic Diet breakfast, lunch, and dinner for 3 days.

    Also known as: ~5-10% kcal carbohydrates diet

  • After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%

    Also known as: Alcohol

06

What researchers measure

Primary outcomes

  1. Change in breath alcohol concentration

    Breath alcohol concentration measured in mg/L of air. The range is .000 to .400 g/L. Change in breath alcohol concentration, pre to post alcohol consumption after 3 day diet intervention during lab day.

    Time frame: 3 hours

Secondary outcomes

  1. Change in motor agility tasks

    Motor agility will be assessed with the grooved pegboard task, in which participants will place pegs onto a metal surface containing 25 keyhole-shaped holes that differ in orientation. Measured in seconds, range 0 to 5 minutes. Change in motor agility tasks pre to post alcohol consumption after 3 day diet intervention.

    Time frame: 3 hours

  2. Change in cognitive performance tasks

    Cognitive performance will be measured with a cued go/no-go task, in which participants will press a computer keyboard key in response to a "go" target and suppress the action in response to a "no-go" target. Measured in % correct responses 0-100. Pre to post alcohol consumption after 3 day diet intervention.

    Time frame: 3 hours

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06065657
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Feb 29, 2024
Primary completion
Dec 1, 2025
Completion
Dec 1, 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Corinde Wiers, Ph.D.
principal investigator · University of Pennsylvania
Henry Kranzler, MD
study director · University of Pennsylvania
Kyle Kampman, MD
study director · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 3-Hydroxybutyric Acid · Butylene glycol · Butylene Glycols · Ethanol

Start the discussion